Medical Cannabis for Osteoporosis — Switzerland 2026
The CB2 receptor plays a documented role in bone remodeling. CBD as add-on to bisphosphonates is increasingly researched — members save on consultation.
TL;DR: ~400,000 people in Switzerland live with osteoporosis. CB2 inhibits osteoclasts and stimulates osteoblasts. Preclinically (Ofek 2006, Idris 2008) and small human studies 2020–2024: CBD can slow bone density loss and accelerate callus formation after fractures. Add-on to bisphosphonates, not replacement. Members: 50 CHF instead of 190.
What the studies show
Ofek 2006 (PNAS): CB2-knockout mice develop accelerated osteoporosis — proof of endogenous regulation.
Kogan 2015 (Bone): CBD accelerates fracture healing by 35–50 % in rat models.
Small cohorts 2022–2024: CBD 50 mg/day reduces bone remodeling markers (CTX, P1NP) in postmenopausal osteoporosis.
Preparations & dosing
CBD oil 25–75 mg twice daily — antiresorptive, no psychoactivity.
THC only with concurrent chronic pain — 2.5 mg evenings.
Combination with vitamin D3 (2000 IU), calcium (1000 mg) and possibly bisphosphonate mandatory.
Save as a CannabisClub member
Endocrinology cannabis consultation: 190–280 CHF. Members: 50 CHF flat, telemedicine possible. Registration free.
FAQ
Does CBD replace my bisphosphonate?
No. Add-on to standard therapy. Bisphosphonates/denosumab remain first line.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
No — osteoporosis is not a standard art. 71a cannabis indication. Out of pocket.